Abbott Reports Positive Results from Parkinson's Drug Trial

Drug developer Abbott has reported interim efficacy and safety results from a Phase III study of levodopa-carbidopa intestinal gel.

US health care major Abbott Laboratories has reported interim efficacy and safety results from a Phase III study of levodopa-carbidopa intestinal gel, used for the treatment of advanced Parkinson's disease.

The open-label, 54-week study included 192 patients and showed that, after 12 weeks of treatment with gel, patients reported a decrease in "off" time and an increase in "on" time without troublesome dyskinesias.

Alberto Espay, assistant professor of neurology at the University of Cincinnati's Neuroscience Institute, said that the interim data showed clinically meaningful improvements in patients.

Levodopa-carbidopa intestinal gel is administered via a surgical